Daewon Pharmaceutical to Resume Manufacture and Sale of Chol Daewon Kids Pen Syrup
Lifting of Ban Prompts Swift Action
Daewon Pharmaceutical, under the leadership of CEO Baek Seung-yeol, has announced its intention to recommence the manufacture and sale of ‘Chol Daewon Kids Pen Syrup’. The decision comes in the wake of the Ministry of Food and Drug Safety lifting the ban on production and sale of the pediatric antipyretic and pain reliever.
In response to the shortage of antipyretic drugs for children, the Ministry of Food and Drug Safety recently indicated that the suspension on Kol Daewon Kids Pen Syrup had been lifted. Promptly acting upon this development, Daewon Pharmaceutical resumed production, initiating with an inaugural supply of 210,000 packs of improved quality products aimed at increasing productivity. Benefiting from the presence of the largest liquid medicine production facility in Jincheon, Chungcheongbuk-do, the company is determined to alleviate the shortage of medicines.
Daewon Pharmaceutical had previously issued a voluntary product recall due to concerns regarding the ‘phase separation phenomenon’ encountered in Cole Daewon Kids Pen Syrup back in May. Following extensive research and consultation, the company has now successfully addressed these issues, reporting the conclusion of the recall to the Food and Drug Safety Administration. In addition, Daewon Pharmaceutical has tirelessly worked towards identifying the root cause and formulating improved solutions. After conducting meticulous experiments and inspections, the company has discovered an optimal ratio and mixing method that ensures stability and prevents phase separation.
A Reputation for Safety
Expressing optimism, an official from Daewon Pharmaceutical stated, “We have collaborated closely with the Ministry of Food and Drug Safety to enhance our formulations and ensure the utmost safety. We are proud to present improved products to consumers and are dedicated to easing the concerns of parents. Our primary focus will be on ramping up production.”
Daewon Pharmaceutical (CEO Baek Seung-yeol) announced on the 11th that it will resume the manufacture and sale of ‘Chol Daewon Kids Pen Syrup’, an antipyretic and pain reliever for children, following the lifting of the ban on manufacture and sale by the Ministry of Food and Drug Safety.
According to Daewon Pharmaceutical, in order to solve the shortage of antipyretic drugs for children, the Ministry of Food and Drug Safety announced on the 10th that the suspension of the manufacture and sale of Kol Daewon Kids Pen Syrup was lifted, and production resumed immediately, starting with’ r initial supply of 210,000 packs of better quality products which will increase productivity. The company plans to solve the shortage of medicines by focusing its efforts on production as it has the largest domestic liquid medicine production facility in Jincheon, Chungcheongbuk-do.
The company previously voluntarily recalled the product as a precautionary measure due to the ‘phase separation phenomenon’ that occurred in Cole Daewon Kids Pen Syrup in May, and reported the end of the recall to the Food and Drug Safety Administration on the end. The department carried out an adequacy assessment. Separately, the company has continued research on identifying the cause and improving formulations. Specifically, Daewon Pharmaceutical’s explanation is that, after thorough experiments and inspections, it has discovered the optimal ratio and mixing method that maintains stability without phase separation.
An official from Daewon Pharmaceutical said, “We have improved formulations based on close cooperation with the Ministry of Food and Drug Safety, and have been recognized for their safety, so that we can present better products to consumers.” We will focus on production so that we can ease parents’ anxiety a little.”
#Daewon #Pharmaceutical #Cole #Daewon #Kids #Pen #Syrup #resume #manufacturing #sales #today